Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Share-based Compensation for 9 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 4.49% to $24.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $99.6 million, a 3.15% decrease, with the full-year FY2025 number at $99.6 million, down 3.15% from a year prior.
  • Share-based Compensation was $24.0 million for Q4 2025 at Denali Therapeutics, down from $25.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $28.1 million in Q1 2023 to a low of $21.0 million in Q3 2021.
  • A 5-year average of $24.8 million and a median of $25.1 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 94.97% in 2021, then fell 9.63% in 2025.
  • Denali Therapeutics' Share-based Compensation stood at $22.1 million in 2021, then grew by 14.05% to $25.2 million in 2022, then rose by 3.18% to $26.0 million in 2023, then dropped by 3.5% to $25.1 million in 2024, then dropped by 4.49% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Share-based Compensation are $24.0 million (Q4 2025), $25.1 million (Q3 2025), and $25.4 million (Q2 2025).